{
    "symbol": "AMPH",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-09 18:29:10",
    "content": " First, strong sales of Primatene Mist are trending towards 100 million in annualized sales by the end of 2024, as the product has seen a 34% year-over-year growth in Q1. On the topic of Amphastar's path towards building our proprietary and biosimilar portfolio, thereby transforming the company towards an established biopharmaceutical profile, Intranasal Naloxone remains on track for re-filing in the second quarter and our Intranasal Epinephrine product maintains its positive progression towards filing next year, as we continue to benefit from fruitful discussions with the agency. Continued strong sales of Glucagon, which launched in February of 2021 also drove growth with sales of $11 million, up 38% from $8 million in the comparable quarter last year. Lidocaine sales growth of 17% to $10.6 million from $9.1 million in the first quarter of 2021 on strong unit demand, while Phytonadione grew 10% to $10.5 million from $9.6 million due to higher average selling prices. In the first quarter, cash flows provided by operations was a very strong $50.8 million."
}